Skip to content Skip to footer
Subscribe Now
Thoughtspot_Saurabh_Chaubey
THOUGHTSPOT

Molecular Farming: Paving a Modern Track for Pharmaceutical Sectors (Molecular Pharming)

Technologies and innovations have transformed the world globally. Traveling to different places, interacting with new people, working remotely from home, and much more comes with evolving technologies. With all these bright perspectives, it’s also an indisputable fact that we are now more susceptible to diseases than we were a few decades ago. After the outbreak…
February 20, 2023

Read more

Disease of the Month: AIDS
INSIGHTS+

Disease of the Month: AIDS

“Putting Ourselves to the Test: Achieving Equity to End HIV”  -Theme of the year 2022  Introduction: HIV/AIDS is one of the top 10 cause of mortality. It is a chronic, epidemic disease caused by human immunodeficiency virus (HIV), a virus that infect WBC’s CD4 T-cell of the immune system. HIV, a type of retrovirus that isn't…
December 20, 2022

Read more

Viewpoints_Tania Small
VIEWPOINTS

Tania Small, VP, Global Medical Oncology Head, GSK, Shares Insights on Target the Future Think Tank Challenge

Shots: Tania spoke about the Target the Future Think Tank Challenge and how it will advance and address key needs in the multiple myeloma  She also talked about GSK’s collaboration with the HealthTree Foundation to provide access, education, and support for underserved communities of multiple myeloma The interview gives a profound understanding of how GSK…
September 14, 2022

Read more

PharmaShots' Key Highlights of Second Quarter 2022
INSIGHTS+

PharmaShots’ Key Highlights of Second Quarter 2022

The second quarter of 2022 highlights major acquisitions in the pharma and biotech industry along with multiple approvals. Meanwhile, AstraZeneca’s Farxiga (dapagliflozin) meet its primary endpoints for heart failure with a preserved ejection fraction Starting with the latest acquisitions, Pfizer acquire Biohaven for ~$11.6B, GSK acquire Affinivax for ~$3.3B. The second quarter of the year…
June 30, 2022

Read more

PharmaShots Interview GSK’ Angela Carroll Shares Insights on First Paper to Define Disease Modification in Systemic Lupus Erythematosus
VIEWPOINTS

PharmaShots Interview: GSK’ Angela Carroll Shares Insights on First Paper to Define Disease Modification in Systemic Lupus Erythematosus

In an interview with PharmaShots, Angela Carroll, US Medical Affairs Scientific Director-Immuno-inflammation at GSK shared her views on a first published article on disease modification in systemic lupus erythematosus, published in Lupus Science & Medicine Shots: The company has published the first research to define disease modification in SLE including LN in the Lupus Science & Medicine. In multiple therapeutic…
May 11, 2022

Read more

PharmaShots Interview GSK’s Tom Corbridge Shares Insights on Nucala as At-Home Treatment Option for Children with Severe Eosinophilic Asthma
VIEWPOINTS

PharmaShots Interview: GSK’s Tom Corbridge Shares Insights on Nucala as At-Home Treatment Option for Children with Severe Eosinophilic Asthma

In an interview with PharmaShots, Tom Corbridge, Senior Medical Lead at GSK shared his views on the approval of its anti-IL-5 biologic NUCALA (mepolizumab) in a 40 mg pre-filled syringe for appropriate children aged 6 to 11 years old with severe eosinophilic asthma (SEA) Shots: Nucala can now be given by a child’s HCPs or administered…
May 4, 2022

Read more

Load more